Search results
Congenital Pigment Disorders May Need Special Management
Medscape· 18 hours agoCongenital disorders of pigmentation are numerous and can have mild to severe effects, and some have...
GENMAB A/S/S (OTCMKTS:GMXAY) and LianBio (NASDAQ:LIAN) Critical Contrast
ETF DAILY NEWS· 3 days agoLianBio (NASDAQ:LIAN – Get Free Report) and GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses ...
Cantor Fitzgerald L. P. Has $362,000 Stock Holdings in Adlai Nortye Ltd. (NASDAQ:ANL)
ETF DAILY NEWS· 18 hours agoCantor Fitzgerald L. P. boosted its position in Adlai Nortye Ltd. (NASDAQ:ANL – Free Report) by 128.2% during the fourth quarter, according to the company in its most recent 13F filing with ...
Replimune (REPL) Gains on Positive Data From Melanoma Study
Zacks· 7 days agoFree Report) announced positive top-line results from the primary analysis of the IGNYTE study on lead pipeline candidate RP1, in combination with Bristol Myers’ (BMY Quick QuoteBMY - Free Report ...
Arkansas woman shares story of winning battle with tongue cancer
KTHV Little Rock· 2 days agoAnn Gibbs and her husband Matt have become familiar with the UAMS Winthrop P. Rockefeller Cancer...
FDA Approves Almirall's Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis on Expanded...
Benzinga· 4 days agoOriginal FDA approval (December 2020) now extended to the use of Klisyri on larger areas of the face or scalp (up to 100 cm2) to address more extensive manifestations of actinic keratosis, driving convenience for both
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 4 days agoFlamingo Therapeutics Announces Poster Presentation at EACR 2024 Congress on FLM-7523 (FTX-001), a First-in-Class Inhibitor of the Long Non-Coding RNA MALAT1 PR Newswire LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, June 10, 2024 LEUVEN
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $66.29 Consensus Target Price from Analysts
ETF DAILY NEWS· 7 days agoJanux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are presently covering the firm, MarketBeat reports ...
Birchview Capital LP Invests $216,000 in Castle Biosciences, Inc. (NASDAQ:CSTL)
ETF DAILY NEWS· 17 hours agoBirchview Capital LP acquired a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 10,000 shares ...
Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above Two Hundred Day Moving Average of...
ETF DAILY NEWS· 5 days agoShares of Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.33 and traded ...